{"ticker": {"uuid": "6a72eedd-4442-4778-8bcd-08744fcbef02", "symbol": "NXTC", "name": "NextCure\u00a0 Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "NextCure (NASDAQ: NXTC) details Avere merger structure and S-4 plan", "summary": "NextCure (NASDAQ: NXTC) has detailed a proposed two-step merger with Avere Therapeutics, Inc., as per an Agreement and Plan of Merger and Reorganization dated July 14, 2026. The initial step involves Neptune Merger Sub Corp. merging into Avere, making Avere a wholly-owned subsidi", "url": "https://www.stocktitan.net/sec-filings/NXTC/425-next-cure-inc-business-combination-communication-e79bbedde131.html", "source_name": "Stock Titan", "published_at": "2026-07-16T21:12:55", "published_display": "16 Jul 2026 21:12", "sentiment": "positive", "sentiment_pct": 61, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Beltsville's NextCure merging with San Francisco startup", "summary": "NextCure Inc., a Beltsville-based biotechnology company focused on cancer treatments, is merging with San Francisco startup Avere Therapeutics in an all-stock deal. NextCure had not yet brought a product to market. The acquisition includes United Therapeutics buying a biotech fir", "url": "https://www.bizjournals.com/washington/news/2026/07/15/nextcure-avere-therapeutics-merger.html", "source_name": "The Business Journals", "published_at": "2026-07-15T11:15:00", "published_display": "15 Jul 2026 11:15", "sentiment": "negative", "sentiment_pct": 40, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure (NXTC) Slides As Avere Merger Triggers Legal Scrutiny", "summary": "NextCure (NXTC) stock has slid by over 12% following news of its merger with Avere Therapeutics, triggering legal scrutiny from multiple investor-rights firms. Shareholders of NextCure are set to own only about 1.21% of the combined company, with a contingent value right for 90% ", "url": "https://stockstotrade.com/news/nextcure-inc-nxtc-news-2026_07_15/", "source_name": "StocksToTrade", "published_at": "2026-07-15T10:05:00", "published_display": "15 Jul 2026 10:05", "sentiment": "negative", "sentiment_pct": 30, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure to Merge With Avere in Stock Deal; $320 Million PIPE to Fund Combined Company", "summary": "NextCure has signed a definitive merger agreement with Avere Therapeutics in a stock-for-stock transaction, which will result in Avere holders owning approximately 98% of the combined company, to be renamed Avere Therapeutics. To finance the merger, Avere secured a $320 million p", "url": "https://www.tradingview.com/news/tradingview:4590771e3ed36:0-nextcure-to-merge-with-avere-in-stock-deal-320-million-pipe-to-fund-combined-company/", "source_name": "TradingView", "published_at": "2026-07-15T09:10:31", "published_display": "15 Jul 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure Announces Transformative All-Stock Merger With Avere", "summary": "NextCure (NXTC) announced an all-stock merger with Avere Therapeutics, creating Avere Therapeutics on Nasdaq under the ticker AVRX. Avere holders and PIPE investors will own 98-99% of the new company, with NextCure shareholders receiving 1-2% plus contingent value rights from leg", "url": "https://www.tipranks.com/news/company-announcements/nextcure-announces-transformative-all-stock-merger-with-avere", "source_name": "TipRanks", "published_at": "2026-07-15T08:43:51", "published_display": "15 Jul 2026 08:43", "sentiment": "negative", "sentiment_pct": 37, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avere, NextCure Merge To Take AVR-001 Ahead In Psoriasis, Ulcerative Colitis", "summary": "Avere and NextCure are merging to advance the development of AVR-001, an oral peptide IL-23 receptor antagonist. This reverse merger aims to target psoriasis and ulcerative colitis with the investigational drug. The companies anticipate that this strategic combination will facili", "url": "https://insights.citeline.com/scrip/business/deals/avere-nextcure-merge-to-take-avr-001-ahead-in-psoriasis-ulcerative-colitis-WJMB6U4WXFGMNNTAC5RCNDE6GA/", "source_name": "Scrip", "published_at": "2026-07-14T21:42:03", "published_display": "14 Jul 2026 21:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did NextCure Stock 3X In One Session? - NextCure (NASDAQ:NXTC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPS2hVY05zZkJuRjNxVUFuakZiMnhRUkg0UnRyb1lkb3dESmxHWDlnZ1lTbVlfRFBQbm5tZFBsZnhfOHpfaEdKM2pnanhHYllZUHg0MW1sOTZ0MmdEX096dVlfeVdjTVlWQV9ZYmR1M0F2eHZxM2xmd1JQTE8zeVdnaDRTdkQ4d3RaeVR5V2U5X1l2VEs3eUxNWGF2QmdIaERHbkxzaE8yNngzMWpCNC1NNnloWUxmUQ?oc=5", "source_name": "Benzinga", "published_at": "2026-07-14T18:09:03+00:00", "published_display": "14 Jul 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of NextCure, Inc. (NASDAQ: NXTC)", "summary": "Monteverde & Associates PC, a class action law firm, has announced an investigation into NextCure, Inc. (NASDAQ: NXTC) regarding its proposed merger with Avere Therapeutics, Inc. The firm is questioning whether the deal, which would leave current NextCure shareholders owning appr", "url": "https://www.prnewswire.com/news-releases/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-nextcure-inc-nasdaq-nxtc-302825382.html", "source_name": "PR Newswire", "published_at": "2026-07-14T17:42:03", "published_display": "14 Jul 2026 17:42", "sentiment": "negative", "sentiment_pct": 29, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure Inc. (NXTC) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live stock quotes and charts for NextCure Inc. (NXTC) on NASDAQ, showing its current price of $5.19, a decrease of $1.39 (-21.10%). The article notes that earnings information is not currently available and there are no analyst ratings within the last three mon", "url": "https://stockstotrade.com/quote/NXTC", "source_name": "StocksToTrade", "published_at": "2026-07-14T16:42:03", "published_display": "14 Jul 2026 16:42", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trending Stocks Today | NextCure Soars 221.55%", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxQRlJpNUJtdVUyZmNldWxWcDdDc3hKdHZRWHlCSmdxakpoOUp5aG5tQ2RVS244QXcybHUwMjZWUXVfNFdSNlY0ZWdkdVgxdFhzTGxoNE9fMmlSbFBZVnNsRG1fdmV3NVprLUlXMDVZd0hZZl93NFhNb2paYVMtbVRhWFVxVGh4bndKbHdwSQ?oc=5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-14T15:25:00+00:00", "published_display": "14 Jul 2026 15:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure skyrockets on Avere reverse-merger deal and $320 million financing plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxONnJCWnZaQm9valBnYklTMEVFZnhIamxVeVZHLXU0QWdtdmI1TlU1aU13dDB2X2ZiOXZSX2w1d25heWJaM3dUNDBsbDF4MGc5d2VCU1NITlE4eUlqdkpHcXMxZi1pMW91cllWWUJNMXVfajE3eHBpMDlaUzdZYVp2VHBEeU9qcENidkM4QmlTUDNnbkNpUnNrSzdIdGs3ZTdnWEh6X0t5SEFiUGJ1dkt6OGZXOUp6dw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-14T14:51:00+00:00", "published_display": "14 Jul 2026 14:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders", "summary": "Ademi LLP is investigating NextCure (NASDAQ: NXTC) for potential breaches of fiduciary duty related to its transaction with Avere Therapeutics. Under the merger terms, NextCure stockholders will hold approximately 1.21% of the combined company, and receive a contingent value righ", "url": "https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-nextcure-inc-is-obtaining-a-fair-price-for-public-shareholders-302825110.html", "source_name": "PR Newswire", "published_at": "2026-07-14T15:42:58", "published_display": "14 Jul 2026 15:42", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure backs Avere merger with $320 million financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxPSGh1ZUZkOUdGUkZxb2ZnQWtISmRIdzY0Rmh1N3pwQUZ5ZVBxUW1PVlJoeFh5NUJpLUFEempWNzdaLW9zY0Z5Y2haOFZ3UXFjZkgtWnc3cVFwSjgzNndFdk5xUzYyRlJLcll3cU9mMkpIbUNnWm5QN0M5Z3RPaDZ6YktMM0VuUWRYUnpj?oc=5", "source_name": "grafa.com", "published_at": "2026-07-14T14:33:00+00:00", "published_display": "14 Jul 2026 14:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its Shareholders", "summary": "Halper Sadeh LLC, an investor rights law firm, is investigating the merger of NextCure, Inc. (NASDAQ: NXTC) with Avere Therapeutics, Inc. The firm is concerned that NextCure and its board may have violated federal securities laws or breached fiduciary duties by not securing the b", "url": "https://www.businesswire.com/news/home/20260714853399/en/NXTC-Stock-Alert-Halper-Sadeh-LLC-is-Investigating-Whether-NextCure-Inc.-is-Obtaining-a-Fair-Price-for-its-Shareholders", "source_name": "Business Wire", "published_at": "2026-07-14T14:42:57", "published_display": "14 Jul 2026 14:42", "sentiment": "negative", "sentiment_pct": 38, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure (NASDAQ: NXTC) plans reverse merger; Avere holders to own about 98%", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNZUszNktSSVR3N09ENElSVU41R2ZDa3B3MF9XczFHWV93d0VqLWJsTGxwNVNobE1jUU5qM2FLN2VyNVAwUWltTGhSVFNoMklxRjZMRkQ4X1VTb3lfQ2pzWFFFQnRESjZEN3Jtbzd1QVpjOVZJbkhUZnFLSWRrLXhHM01BMFJ5MEVpU25FdDgzMDZaREt3bGI5ZEZDNjRQMlBJWUc0RTNKZXl4MEVxQkI2amRpUGg?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T11:03:34+00:00", "published_display": "14 Jul 2026 11:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure (NASDAQ: NXTC) sets Avere merger backed by $320M raise", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQaGRhTXlCaFR3cXg5SXpKUHh6ejRWU3R0SUZscEdlOWJRbDlZTHl0S1JwZ1U2S1VGY3BsYnRaeFFWT1FILVcwX2NHdW10VEdhZ0FaclNydWdteVhZc1YybVk4S3FOZlprdnRCQzdaYjZwUVZaaTdhMmd6cFowNE5SR2J6WFJlWGd3Mkp1M1UtSHVmVUVNd2J0b2xIMEZubWhCZk9Ybg?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T11:01:33+00:00", "published_display": "14 Jul 2026 11:01", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure to Merge With Avere Therapeutics in All-Stock Deal", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/nextcure-merge-avere-therapeutics-stock-103253385.html", "source_name": "MT Newswires", "published_at": "2026-07-14T10:32:53+00:00", "published_display": "14 Jul 2026 10:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/nextcure-avere-therapeutics-announce-merger-100000778.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T10:00:00+00:00", "published_display": "14 Jul 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure to merge with Avere Therapeutics in $320M deal", "summary": "NextCure, Inc. has announced an all-stock merger agreement with privately-held Avere Therapeutics, Inc., valued at $320 million, which includes a concurrent private placement. Upon completion, the combined entity will operate as Avere Therapeutics, Inc. and trade under AVRX on Na", "url": "https://www.investing.com/news/company-news/nextcure-to-merge-with-avere-therapeutics-in-320m-deal-93CH-4790166", "source_name": "Investing.com", "published_at": "2026-07-14T10:42:58", "published_display": "14 Jul 2026 10:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure to merge with privately-held Avere (NXTC:NASDAQ)", "summary": "NextCure (NXTC) announced an all-stock merger agreement with privately held Avere Therapeutics, a biotech company specializing in inflammatory diseases. This news caused NextCure's shares to surge over 200% in premarket trading. The combined entities also revealed a $320 million ", "url": "https://seekingalpha.com/news/4613491-nextcure-merge-privately-held-avere", "source_name": "Seeking Alpha", "published_at": "2026-07-14T10:42:57", "published_display": "14 Jul 2026 10:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avere anticipates early 2027 Phase 2b start for oral psoriasis therapy", "summary": "NextCure (Nasdaq: NXTC) and Avere Therapeutics announced an all-stock merger to advance Avere's oral IL-23 program, AVR-001, for inflammatory diseases. The combined company, to be named Avere Therapeutics (\"AVRX\"), secured $320 million in private financing, including $251 million", "url": "https://www.stocktitan.net/news/NXTC/next-cure-and-avere-therapeutics-announce-merger-to-advance-once-x7fui81xwnmx.html", "source_name": "Stock Titan", "published_at": "2026-07-14T09:42:57", "published_display": "14 Jul 2026 09:42", "sentiment": "negative", "sentiment_pct": 29, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to sales forward of NextCure, Inc. \u2013 NASDAQ:NXTC", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOXzNoV3pUQS0zTEtDYlUzLTkwRG1KZ0tpU043QTZwcjF5UmpWZkI3akxNOXZXZnY3S0I5N3EzLWNGMUVEUUxFQk5zZWluT0tUWkp1MkR2R3ZQM1ViMDJNWkxNNXhTMFk3MUVPVTQyX1E2RDJuekxjRGxZMWtjNXF1Mi1OZ1ZOMEwySU14NFUzWVZjTzZpZ0N0TGF6blBEdw?oc=5", "source_name": "TradingView", "published_at": "2026-07-12T22:22:30+00:00", "published_display": "12 Jul 2026 22:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of NextCure, Inc. \u2013 NASDAQ:NXTC", "summary": "This article displays the enterprise value to EBITDA forward for NextCure, Inc. (NASDAQ: NXTC), as found on TradingView. It appears to be a financial data point within a larger platform, with no additional textual analysis or context provided in the snippet. The content primarily", "url": "https://www.tradingview.com/symbols/NASDAQ-NXTC/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T19:41:02", "published_display": "10 Jul 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of NextCure, Inc. \u2013 MUN:2US0", "summary": "This article focuses on the enterprise value to EBITDA forward for NextCure, Inc. (MUN:2US0). It provides a financial metric within the context of the company's trading information on the Munich Stock Exchange, highlighting that the market is currently closed with no trades.", "url": "https://www.tradingview.com/symbols/MUN-2US0/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T04:41:21", "published_display": "10 Jul 2026 04:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure (NXTC) H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference summary", "summary": "NextCure (NXTC) presented its lead candidate, NC-181, a humanized monoclonal antibody targeting APOE for Alzheimer's disease, at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference. Preclinical studies indicate NC-181 reduces amyloid pathology and improves vascul", "url": "https://quartr.com/events/nextcure-nxtc-h-c-wainwright-5th-annual-neuro-perspectives-virtual-conference_Fk1fMZTz", "source_name": "Quartr", "published_at": "2026-07-09T06:41:21", "published_display": "09 Jul 2026 06:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure Company Profile & Introduction", "summary": "This document provides a company profile and introduction for NextCure. It is likely a brief overview intended to present key information about the company.", "url": "https://www.moomoo.com/stock/NXTC-US/company?from=share&stockId=206117", "source_name": "Moomoo", "published_at": "2026-07-08T19:10:45", "published_display": "08 Jul 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NXTC - Nextcure Inc Options", "summary": "This article provides a detailed financial overview of Nextcure Inc (NXTC), including its stock performance, key financial metrics, and insider/institutional ownership. The company's stock recently closed at $2.14, showing a 13.71% increase for the day. Financial data highlights ", "url": "https://finviz.com/stock?t=NXTC&ty=oc&p=w&b=1", "source_name": "Finviz", "published_at": "2026-07-02T18:11:08", "published_display": "02 Jul 2026 18:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of NextCure, Inc. \u2013 NASDAQ:NXTC", "summary": "This article provides financial information for NextCure, Inc. (NASDAQ: NXTC), focusing on its forward price-to-book ratio. The content appears to be a stub or a placeholder from a financial data platform, indicating the company's stock market status and various financial and com", "url": "https://www.tradingview.com/symbols/NASDAQ-NXTC/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T01:09:22", "published_display": "29 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure, Inc. Actuals & Estimates (NASDAQ:NXTC)", "summary": "NextCure, Inc. (NXTC) stock is currently priced at $1.65, having experienced significant declines over the past week, month, and year. Analysts provide a wide forecast range for NXTC, with a maximum estimate of $25.00 and a minimum of $15.00. The company's next earnings report is", "url": "https://www.tradingview.com/symbols/NASDAQ-NXTC/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T03:08:50", "published_display": "27 Jun 2026 03:08", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure, Inc. Actuals & Estimates (FWB:2US0)", "summary": "This article provides financial actuals and estimates for NextCure, Inc. (FWB:2US0), including analyst price targets, historical stock performance, and upcoming earnings reports. It details the company's past earnings and revenue, current net income, employee count, and confirms ", "url": "https://www.tradingview.com/symbols/FWB-2US0/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T21:40:37", "published_display": "26 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NXTC Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "NextCure, Inc. (NXTC) has a current stock price of $1.65, with analysts providing a wide forecast range for its future price, from a minimum of $15.00 to a maximum of $25.00. The stock has experienced significant declines recently, falling 25.23% in the past week and 77.28% in th", "url": "https://www.tradingview.com/symbols/NASDAQ-NXTC/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T14:40:30", "published_display": "26 Jun 2026 14:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure Inc (NXTC) Valuation: PE, PB & Fair Value Analysis", "summary": "NextCure Inc (NXTC) has a current valuation score of 7.28, placing it 242 out of 387 in the Biotechnology & Medical Research industry, with its score decreasing by 1.6 from the previous 8.88. The company's current P/E ratio is -0.10, which is significantly below its recent high b", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nxtc/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-26T10:39:53", "published_display": "26 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure, Inc. Actuals & Estimates (BOATS:NXTC)", "summary": "This article provides an overview of NextCure, Inc. (NXTC) financials, including actuals and estimates, price targets, and historical performance. It details the company's past earnings, revenue, net income, and upcoming earnings report date. Additionally, it addresses common inv", "url": "https://www.tradingview.com/symbols/BOATS-NXTC/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T09:39:53", "published_display": "26 Jun 2026 09:39", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure (NASDAQ: NXTC) shareholders back amended 2019 incentive plan and director slate", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPV3hPeGE4bjhVVEdqZDNsQ1phQlZnZzl1b1QtLVR4bTNhZDZvVldwR05BLVRBXzM4UzJKclJOX3FYLTVTSzBYbzZBSGxQVEJ3QzB5MFBsWkJ0emNMMEhsYi1kMmhuSzFnaTVTR0hXMFA3ZklrS0g1MEJjS3NMSEdKUFIxZlk1eWdQbjlfOEVYdzk3bExBYWJxMEJEbTNGdUVES3E5aw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure (NXTC) director awarded options for 2,340 shares at $2.02", "summary": "NextCure, Inc. director Elaine V. Jones was granted options to acquire 2,340 shares of common stock at an exercise price of $2.02 per share, expiring on June 17, 2036. This grant vests in full on the earlier of June 18, 2027, or the date of the company's 2027 annual meeting of st", "url": "https://www.stocktitan.net/sec-filings/NXTC/form-4-next-cure-inc-insider-trading-activity-81e94028b8f7.html", "source_name": "Stock Titan", "published_at": "2026-06-23T14:08:50", "published_display": "23 Jun 2026 14:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure (NXTC) director receives 2,340 options at $2.02 strike", "summary": "NextCure, Inc. director Anne Elizabeth Borgman was granted 2,340 stock options at an exercise price of $2.02 per share. These options will vest in full on the earlier of June 18, 2027, or the 2027 Annual Meeting of Stockholders, and are set to expire on June 17, 2036. Following t", "url": "https://www.stocktitan.net/sec-filings/NXTC/form-4-next-cure-inc-insider-trading-activity-708837fac04d.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:11:03", "published_display": "22 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure (NXTC) director awarded 2,340 options at $2.02 exercise price", "summary": "NextCure, Inc. (NXTC) director Stephen W. Webster was granted 2,340 stock options with an exercise price of $2.02 per share, expiring on June 17, 2036. The options will vest in full on the earlier of June 18, 2027, or the company's 2027 Annual Meeting of Stockholders. This grant ", "url": "https://www.stocktitan.net/sec-filings/NXTC/form-4-next-cure-inc-insider-trading-activity-5776452516c2.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:10:21", "published_display": "22 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at NextCure (NASDAQ: NXTC) granted 2,340 stock options", "summary": "NextCure, Inc. director Ellen Feigal was granted 2,340 stock options with an exercise price of $2.02 per share, expiring on June 17, 2036. These options vest fully on the earlier of June 18, 2027, or the date of NextCure\u2019s 2027 Annual Meeting of Stockholders. This transaction is ", "url": "https://www.stocktitan.net/sec-filings/NXTC/form-4-next-cure-inc-insider-trading-activity-eff2ac564db8.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:10:21", "published_display": "22 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure (NASDAQ: NXTC) director receives stock options grant for 3,510 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOUENOMXJ1NjFNdTBUeTJ6TTFRYzJCMlQ1aTBUdVQzc05WVW9ZekxpOGlXcU12SHZUZk9HaHl5V2lKWTF1a3dmbHY1ZGFyRWFfWWtIalpMc3plT3lBYU93QXdSZFZGOGVGTDlUSWxxeVNoT09McTdUMVphMUdVMnh3UXJ1d18wdWN0SDcxYVo1em5NbWZGSjRjRk5WOU5lZG9vMklQV3d6aGFaMG8?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "NextCure Raises $21.5M to Extend Runway and Advance ADC Programs", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQS3E3R204NzFaa1BQbjFOcXF0NmtPM1VHTnlYa3VMc0kyZk1oZU5QTFBJUkE0eS1MUmJsMXZjeWhJSnMwbjNIYzEwUG51TVNBS1hQWW0wRl9rMGFWZ1RSTmQxRVRfc3IxT251bE41WU9HbE5FTFExSFlPM0ZSTTlyTm9yUHlFYW9jby11NHRYWWJ0Zw?oc=5", "source_name": "BioBuzz", "published_at": "2025-11-12T08:00:00+00:00", "published_display": "12 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why NextCure (NASDAQ:NXTC) Must Use Its Cash Wisely", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-18T07:00:00+00:00", "published_display": "18 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure's Dual ADC Cancer Programs Progress: Strategic Partnership Fuels Clinical Advancement", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxObUZwUHNwZFU5SkNvLUhGV1B2SDBnYkY3T3Vxcl9DU1ZldnBBVWltX3U5dkRNc3l4SkZock9qQXladGhIQ3BabXhocldTNkNyejdZRUZHcUt6b0VnSDd6ZktqajF2N0VsVm92MGlkcFZvUHpyb0VhY3JxcHIyaE9rUkk0aWRKdFhpQWx5V19ocHhBSHAyQVJvTXBJcjJPNVBvVUtsTkpsTVlKV2hUOURrbXFobXV3aHhYQ0VjUkpn?oc=5", "source_name": "Stock Titan", "published_at": "2025-08-07T20:06:58+00:00", "published_display": "07 Aug 2025 20:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "NextCure (NASDAQ: NXTC) details Avere merger structure and S-4 plan", "summary": "NextCure (NASDAQ: NXTC) has detailed a proposed two-step merger with Avere Therapeutics, Inc., as per an Agreement and Plan of Merger and Reorganization dated July 14, 2026. The initial step involves Neptune Merger Sub Corp. merging into Avere, making Avere a wholly-owned subsidi", "url": "https://www.stocktitan.net/sec-filings/NXTC/425-next-cure-inc-business-combination-communication-e79bbedde131.html", "source_name": "Stock Titan", "published_at": "2026-07-16T21:12:55", "published_display": "16 Jul 2026 21:12", "sentiment": "positive", "sentiment_pct": 61, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beltsville's NextCure merging with San Francisco startup", "summary": "NextCure Inc., a Beltsville-based biotechnology company focused on cancer treatments, is merging with San Francisco startup Avere Therapeutics in an all-stock deal. NextCure had not yet brought a product to market. The acquisition includes United Therapeutics buying a biotech fir", "url": "https://www.bizjournals.com/washington/news/2026/07/15/nextcure-avere-therapeutics-merger.html", "source_name": "The Business Journals", "published_at": "2026-07-15T11:15:00", "published_display": "15 Jul 2026 11:15", "sentiment": "negative", "sentiment_pct": 40, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure (NXTC) Slides As Avere Merger Triggers Legal Scrutiny", "summary": "NextCure (NXTC) stock has slid by over 12% following news of its merger with Avere Therapeutics, triggering legal scrutiny from multiple investor-rights firms. Shareholders of NextCure are set to own only about 1.21% of the combined company, with a contingent value right for 90% ", "url": "https://stockstotrade.com/news/nextcure-inc-nxtc-news-2026_07_15/", "source_name": "StocksToTrade", "published_at": "2026-07-15T10:05:00", "published_display": "15 Jul 2026 10:05", "sentiment": "negative", "sentiment_pct": 30, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure to Merge With Avere in Stock Deal; $320 Million PIPE to Fund Combined Company", "summary": "NextCure has signed a definitive merger agreement with Avere Therapeutics in a stock-for-stock transaction, which will result in Avere holders owning approximately 98% of the combined company, to be renamed Avere Therapeutics. To finance the merger, Avere secured a $320 million p", "url": "https://www.tradingview.com/news/tradingview:4590771e3ed36:0-nextcure-to-merge-with-avere-in-stock-deal-320-million-pipe-to-fund-combined-company/", "source_name": "TradingView", "published_at": "2026-07-15T09:10:31", "published_display": "15 Jul 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure Announces Transformative All-Stock Merger With Avere", "summary": "NextCure (NXTC) announced an all-stock merger with Avere Therapeutics, creating Avere Therapeutics on Nasdaq under the ticker AVRX. Avere holders and PIPE investors will own 98-99% of the new company, with NextCure shareholders receiving 1-2% plus contingent value rights from leg", "url": "https://www.tipranks.com/news/company-announcements/nextcure-announces-transformative-all-stock-merger-with-avere", "source_name": "TipRanks", "published_at": "2026-07-15T08:43:51", "published_display": "15 Jul 2026 08:43", "sentiment": "negative", "sentiment_pct": 37, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avere, NextCure Merge To Take AVR-001 Ahead In Psoriasis, Ulcerative Colitis", "summary": "Avere and NextCure are merging to advance the development of AVR-001, an oral peptide IL-23 receptor antagonist. This reverse merger aims to target psoriasis and ulcerative colitis with the investigational drug. The companies anticipate that this strategic combination will facili", "url": "https://insights.citeline.com/scrip/business/deals/avere-nextcure-merge-to-take-avr-001-ahead-in-psoriasis-ulcerative-colitis-WJMB6U4WXFGMNNTAC5RCNDE6GA/", "source_name": "Scrip", "published_at": "2026-07-14T21:42:03", "published_display": "14 Jul 2026 21:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did NextCure Stock 3X In One Session? - NextCure (NASDAQ:NXTC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPS2hVY05zZkJuRjNxVUFuakZiMnhRUkg0UnRyb1lkb3dESmxHWDlnZ1lTbVlfRFBQbm5tZFBsZnhfOHpfaEdKM2pnanhHYllZUHg0MW1sOTZ0MmdEX096dVlfeVdjTVlWQV9ZYmR1M0F2eHZxM2xmd1JQTE8zeVdnaDRTdkQ4d3RaeVR5V2U5X1l2VEs3eUxNWGF2QmdIaERHbkxzaE8yNngzMWpCNC1NNnloWUxmUQ?oc=5", "source_name": "Benzinga", "published_at": "2026-07-14T18:09:03+00:00", "published_display": "14 Jul 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of NextCure, Inc. (NASDAQ: NXTC)", "summary": "Monteverde & Associates PC, a class action law firm, has announced an investigation into NextCure, Inc. (NASDAQ: NXTC) regarding its proposed merger with Avere Therapeutics, Inc. The firm is questioning whether the deal, which would leave current NextCure shareholders owning appr", "url": "https://www.prnewswire.com/news-releases/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-nextcure-inc-nasdaq-nxtc-302825382.html", "source_name": "PR Newswire", "published_at": "2026-07-14T17:42:03", "published_display": "14 Jul 2026 17:42", "sentiment": "negative", "sentiment_pct": 29, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure Inc. (NXTC) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live stock quotes and charts for NextCure Inc. (NXTC) on NASDAQ, showing its current price of $5.19, a decrease of $1.39 (-21.10%). The article notes that earnings information is not currently available and there are no analyst ratings within the last three mon", "url": "https://stockstotrade.com/quote/NXTC", "source_name": "StocksToTrade", "published_at": "2026-07-14T16:42:03", "published_display": "14 Jul 2026 16:42", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trending Stocks Today | NextCure Soars 221.55%", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxQRlJpNUJtdVUyZmNldWxWcDdDc3hKdHZRWHlCSmdxakpoOUp5aG5tQ2RVS244QXcybHUwMjZWUXVfNFdSNlY0ZWdkdVgxdFhzTGxoNE9fMmlSbFBZVnNsRG1fdmV3NVprLUlXMDVZd0hZZl93NFhNb2paYVMtbVRhWFVxVGh4bndKbHdwSQ?oc=5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-14T15:25:00+00:00", "published_display": "14 Jul 2026 15:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure skyrockets on Avere reverse-merger deal and $320 million financing plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxONnJCWnZaQm9valBnYklTMEVFZnhIamxVeVZHLXU0QWdtdmI1TlU1aU13dDB2X2ZiOXZSX2w1d25heWJaM3dUNDBsbDF4MGc5d2VCU1NITlE4eUlqdkpHcXMxZi1pMW91cllWWUJNMXVfajE3eHBpMDlaUzdZYVp2VHBEeU9qcENidkM4QmlTUDNnbkNpUnNrSzdIdGs3ZTdnWEh6X0t5SEFiUGJ1dkt6OGZXOUp6dw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-14T14:51:00+00:00", "published_display": "14 Jul 2026 14:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders", "summary": "Ademi LLP is investigating NextCure (NASDAQ: NXTC) for potential breaches of fiduciary duty related to its transaction with Avere Therapeutics. Under the merger terms, NextCure stockholders will hold approximately 1.21% of the combined company, and receive a contingent value righ", "url": "https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-nextcure-inc-is-obtaining-a-fair-price-for-public-shareholders-302825110.html", "source_name": "PR Newswire", "published_at": "2026-07-14T15:42:58", "published_display": "14 Jul 2026 15:42", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure backs Avere merger with $320 million financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxPSGh1ZUZkOUdGUkZxb2ZnQWtISmRIdzY0Rmh1N3pwQUZ5ZVBxUW1PVlJoeFh5NUJpLUFEempWNzdaLW9zY0Z5Y2haOFZ3UXFjZkgtWnc3cVFwSjgzNndFdk5xUzYyRlJLcll3cU9mMkpIbUNnWm5QN0M5Z3RPaDZ6YktMM0VuUWRYUnpj?oc=5", "source_name": "grafa.com", "published_at": "2026-07-14T14:33:00+00:00", "published_display": "14 Jul 2026 14:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its Shareholders", "summary": "Halper Sadeh LLC, an investor rights law firm, is investigating the merger of NextCure, Inc. (NASDAQ: NXTC) with Avere Therapeutics, Inc. The firm is concerned that NextCure and its board may have violated federal securities laws or breached fiduciary duties by not securing the b", "url": "https://www.businesswire.com/news/home/20260714853399/en/NXTC-Stock-Alert-Halper-Sadeh-LLC-is-Investigating-Whether-NextCure-Inc.-is-Obtaining-a-Fair-Price-for-its-Shareholders", "source_name": "Business Wire", "published_at": "2026-07-14T14:42:57", "published_display": "14 Jul 2026 14:42", "sentiment": "negative", "sentiment_pct": 38, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure (NASDAQ: NXTC) plans reverse merger; Avere holders to own about 98%", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNZUszNktSSVR3N09ENElSVU41R2ZDa3B3MF9XczFHWV93d0VqLWJsTGxwNVNobE1jUU5qM2FLN2VyNVAwUWltTGhSVFNoMklxRjZMRkQ4X1VTb3lfQ2pzWFFFQnRESjZEN3Jtbzd1QVpjOVZJbkhUZnFLSWRrLXhHM01BMFJ5MEVpU25FdDgzMDZaREt3bGI5ZEZDNjRQMlBJWUc0RTNKZXl4MEVxQkI2amRpUGg?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T11:03:34+00:00", "published_display": "14 Jul 2026 11:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure (NASDAQ: NXTC) sets Avere merger backed by $320M raise", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQaGRhTXlCaFR3cXg5SXpKUHh6ejRWU3R0SUZscEdlOWJRbDlZTHl0S1JwZ1U2S1VGY3BsYnRaeFFWT1FILVcwX2NHdW10VEdhZ0FaclNydWdteVhZc1YybVk4S3FOZlprdnRCQzdaYjZwUVZaaTdhMmd6cFowNE5SR2J6WFJlWGd3Mkp1M1UtSHVmVUVNd2J0b2xIMEZubWhCZk9Ybg?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T11:01:33+00:00", "published_display": "14 Jul 2026 11:01", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure to Merge With Avere Therapeutics in All-Stock Deal", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/nextcure-merge-avere-therapeutics-stock-103253385.html", "source_name": "MT Newswires", "published_at": "2026-07-14T10:32:53+00:00", "published_display": "14 Jul 2026 10:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/nextcure-avere-therapeutics-announce-merger-100000778.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T10:00:00+00:00", "published_display": "14 Jul 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure to merge with Avere Therapeutics in $320M deal", "summary": "NextCure, Inc. has announced an all-stock merger agreement with privately-held Avere Therapeutics, Inc., valued at $320 million, which includes a concurrent private placement. Upon completion, the combined entity will operate as Avere Therapeutics, Inc. and trade under AVRX on Na", "url": "https://www.investing.com/news/company-news/nextcure-to-merge-with-avere-therapeutics-in-320m-deal-93CH-4790166", "source_name": "Investing.com", "published_at": "2026-07-14T10:42:58", "published_display": "14 Jul 2026 10:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure to merge with privately-held Avere (NXTC:NASDAQ)", "summary": "NextCure (NXTC) announced an all-stock merger agreement with privately held Avere Therapeutics, a biotech company specializing in inflammatory diseases. This news caused NextCure's shares to surge over 200% in premarket trading. The combined entities also revealed a $320 million ", "url": "https://seekingalpha.com/news/4613491-nextcure-merge-privately-held-avere", "source_name": "Seeking Alpha", "published_at": "2026-07-14T10:42:57", "published_display": "14 Jul 2026 10:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avere anticipates early 2027 Phase 2b start for oral psoriasis therapy", "summary": "NextCure (Nasdaq: NXTC) and Avere Therapeutics announced an all-stock merger to advance Avere's oral IL-23 program, AVR-001, for inflammatory diseases. The combined company, to be named Avere Therapeutics (\"AVRX\"), secured $320 million in private financing, including $251 million", "url": "https://www.stocktitan.net/news/NXTC/next-cure-and-avere-therapeutics-announce-merger-to-advance-once-x7fui81xwnmx.html", "source_name": "Stock Titan", "published_at": "2026-07-14T09:42:57", "published_display": "14 Jul 2026 09:42", "sentiment": "negative", "sentiment_pct": 29, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of NextCure, Inc. \u2013 NASDAQ:NXTC", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOXzNoV3pUQS0zTEtDYlUzLTkwRG1KZ0tpU043QTZwcjF5UmpWZkI3akxNOXZXZnY3S0I5N3EzLWNGMUVEUUxFQk5zZWluT0tUWkp1MkR2R3ZQM1ViMDJNWkxNNXhTMFk3MUVPVTQyX1E2RDJuekxjRGxZMWtjNXF1Mi1OZ1ZOMEwySU14NFUzWVZjTzZpZ0N0TGF6blBEdw?oc=5", "source_name": "TradingView", "published_at": "2026-07-12T22:22:30+00:00", "published_display": "12 Jul 2026 22:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of NextCure, Inc. \u2013 NASDAQ:NXTC", "summary": "This article displays the enterprise value to EBITDA forward for NextCure, Inc. (NASDAQ: NXTC), as found on TradingView. It appears to be a financial data point within a larger platform, with no additional textual analysis or context provided in the snippet. The content primarily", "url": "https://www.tradingview.com/symbols/NASDAQ-NXTC/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T19:41:02", "published_display": "10 Jul 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of NextCure, Inc. \u2013 MUN:2US0", "summary": "This article focuses on the enterprise value to EBITDA forward for NextCure, Inc. (MUN:2US0). It provides a financial metric within the context of the company's trading information on the Munich Stock Exchange, highlighting that the market is currently closed with no trades.", "url": "https://www.tradingview.com/symbols/MUN-2US0/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T04:41:21", "published_display": "10 Jul 2026 04:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure (NXTC) H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference summary", "summary": "NextCure (NXTC) presented its lead candidate, NC-181, a humanized monoclonal antibody targeting APOE for Alzheimer's disease, at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference. Preclinical studies indicate NC-181 reduces amyloid pathology and improves vascul", "url": "https://quartr.com/events/nextcure-nxtc-h-c-wainwright-5th-annual-neuro-perspectives-virtual-conference_Fk1fMZTz", "source_name": "Quartr", "published_at": "2026-07-09T06:41:21", "published_display": "09 Jul 2026 06:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure Company Profile & Introduction", "summary": "This document provides a company profile and introduction for NextCure. It is likely a brief overview intended to present key information about the company.", "url": "https://www.moomoo.com/stock/NXTC-US/company?from=share&stockId=206117", "source_name": "Moomoo", "published_at": "2026-07-08T19:10:45", "published_display": "08 Jul 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NXTC - Nextcure Inc Options", "summary": "This article provides a detailed financial overview of Nextcure Inc (NXTC), including its stock performance, key financial metrics, and insider/institutional ownership. The company's stock recently closed at $2.14, showing a 13.71% increase for the day. Financial data highlights ", "url": "https://finviz.com/stock?t=NXTC&ty=oc&p=w&b=1", "source_name": "Finviz", "published_at": "2026-07-02T18:11:08", "published_display": "02 Jul 2026 18:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of NextCure, Inc. \u2013 NASDAQ:NXTC", "summary": "This article provides financial information for NextCure, Inc. (NASDAQ: NXTC), focusing on its forward price-to-book ratio. The content appears to be a stub or a placeholder from a financial data platform, indicating the company's stock market status and various financial and com", "url": "https://www.tradingview.com/symbols/NASDAQ-NXTC/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T01:09:22", "published_display": "29 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure, Inc. Actuals & Estimates (NASDAQ:NXTC)", "summary": "NextCure, Inc. (NXTC) stock is currently priced at $1.65, having experienced significant declines over the past week, month, and year. Analysts provide a wide forecast range for NXTC, with a maximum estimate of $25.00 and a minimum of $15.00. The company's next earnings report is", "url": "https://www.tradingview.com/symbols/NASDAQ-NXTC/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T03:08:50", "published_display": "27 Jun 2026 03:08", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure, Inc. Actuals & Estimates (FWB:2US0)", "summary": "This article provides financial actuals and estimates for NextCure, Inc. (FWB:2US0), including analyst price targets, historical stock performance, and upcoming earnings reports. It details the company's past earnings and revenue, current net income, employee count, and confirms ", "url": "https://www.tradingview.com/symbols/FWB-2US0/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T21:40:37", "published_display": "26 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NXTC Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "NextCure, Inc. (NXTC) has a current stock price of $1.65, with analysts providing a wide forecast range for its future price, from a minimum of $15.00 to a maximum of $25.00. The stock has experienced significant declines recently, falling 25.23% in the past week and 77.28% in th", "url": "https://www.tradingview.com/symbols/NASDAQ-NXTC/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T14:40:30", "published_display": "26 Jun 2026 14:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure Inc (NXTC) Valuation: PE, PB & Fair Value Analysis", "summary": "NextCure Inc (NXTC) has a current valuation score of 7.28, placing it 242 out of 387 in the Biotechnology & Medical Research industry, with its score decreasing by 1.6 from the previous 8.88. The company's current P/E ratio is -0.10, which is significantly below its recent high b", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nxtc/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-26T10:39:53", "published_display": "26 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure, Inc. Actuals & Estimates (BOATS:NXTC)", "summary": "This article provides an overview of NextCure, Inc. (NXTC) financials, including actuals and estimates, price targets, and historical performance. It details the company's past earnings, revenue, net income, and upcoming earnings report date. Additionally, it addresses common inv", "url": "https://www.tradingview.com/symbols/BOATS-NXTC/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T09:39:53", "published_display": "26 Jun 2026 09:39", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure (NASDAQ: NXTC) shareholders back amended 2019 incentive plan and director slate", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPV3hPeGE4bjhVVEdqZDNsQ1phQlZnZzl1b1QtLVR4bTNhZDZvVldwR05BLVRBXzM4UzJKclJOX3FYLTVTSzBYbzZBSGxQVEJ3QzB5MFBsWkJ0emNMMEhsYi1kMmhuSzFnaTVTR0hXMFA3ZklrS0g1MEJjS3NMSEdKUFIxZlk1eWdQbjlfOEVYdzk3bExBYWJxMEJEbTNGdUVES3E5aw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure (NXTC) director awarded options for 2,340 shares at $2.02", "summary": "NextCure, Inc. director Elaine V. Jones was granted options to acquire 2,340 shares of common stock at an exercise price of $2.02 per share, expiring on June 17, 2036. This grant vests in full on the earlier of June 18, 2027, or the date of the company's 2027 annual meeting of st", "url": "https://www.stocktitan.net/sec-filings/NXTC/form-4-next-cure-inc-insider-trading-activity-81e94028b8f7.html", "source_name": "Stock Titan", "published_at": "2026-06-23T14:08:50", "published_display": "23 Jun 2026 14:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure (NXTC) director receives 2,340 options at $2.02 strike", "summary": "NextCure, Inc. director Anne Elizabeth Borgman was granted 2,340 stock options at an exercise price of $2.02 per share. These options will vest in full on the earlier of June 18, 2027, or the 2027 Annual Meeting of Stockholders, and are set to expire on June 17, 2036. Following t", "url": "https://www.stocktitan.net/sec-filings/NXTC/form-4-next-cure-inc-insider-trading-activity-708837fac04d.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:11:03", "published_display": "22 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure (NXTC) director awarded 2,340 options at $2.02 exercise price", "summary": "NextCure, Inc. (NXTC) director Stephen W. Webster was granted 2,340 stock options with an exercise price of $2.02 per share, expiring on June 17, 2036. The options will vest in full on the earlier of June 18, 2027, or the company's 2027 Annual Meeting of Stockholders. This grant ", "url": "https://www.stocktitan.net/sec-filings/NXTC/form-4-next-cure-inc-insider-trading-activity-5776452516c2.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:10:21", "published_display": "22 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at NextCure (NASDAQ: NXTC) granted 2,340 stock options", "summary": "NextCure, Inc. director Ellen Feigal was granted 2,340 stock options with an exercise price of $2.02 per share, expiring on June 17, 2036. These options vest fully on the earlier of June 18, 2027, or the date of NextCure\u2019s 2027 Annual Meeting of Stockholders. This transaction is ", "url": "https://www.stocktitan.net/sec-filings/NXTC/form-4-next-cure-inc-insider-trading-activity-eff2ac564db8.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:10:21", "published_display": "22 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure (NASDAQ: NXTC) director receives stock options grant for 3,510 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOUENOMXJ1NjFNdTBUeTJ6TTFRYzJCMlQ1aTBUdVQzc05WVW9ZekxpOGlXcU12SHZUZk9HaHl5V2lKWTF1a3dmbHY1ZGFyRWFfWWtIalpMc3plT3lBYU93QXdSZFZGOGVGTDlUSWxxeVNoT09McTdUMVphMUdVMnh3UXJ1d18wdWN0SDcxYVo1em5NbWZGSjRjRk5WOU5lZG9vMklQV3d6aGFaMG8?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure Raises $21.5M to Extend Runway and Advance ADC Programs", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQS3E3R204NzFaa1BQbjFOcXF0NmtPM1VHTnlYa3VMc0kyZk1oZU5QTFBJUkE0eS1MUmJsMXZjeWhJSnMwbjNIYzEwUG51TVNBS1hQWW0wRl9rMGFWZ1RSTmQxRVRfc3IxT251bE41WU9HbE5FTFExSFlPM0ZSTTlyTm9yUHlFYW9jby11NHRYWWJ0Zw?oc=5", "source_name": "BioBuzz", "published_at": "2025-11-12T08:00:00+00:00", "published_display": "12 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why NextCure (NASDAQ:NXTC) Must Use Its Cash Wisely", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-18T07:00:00+00:00", "published_display": "18 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NextCure's Dual ADC Cancer Programs Progress: Strategic Partnership Fuels Clinical Advancement", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxObUZwUHNwZFU5SkNvLUhGV1B2SDBnYkY3T3Vxcl9DU1ZldnBBVWltX3U5dkRNc3l4SkZock9qQXladGhIQ3BabXhocldTNkNyejdZRUZHcUt6b0VnSDd6ZktqajF2N0VsVm92MGlkcFZvUHpyb0VhY3JxcHIyaE9rUkk0aWRKdFhpQWx5V19ocHhBSHAyQVJvTXBJcjJPNVBvVUtsTkpsTVlKV2hUOURrbXFobXV3aHhYQ0VjUkpn?oc=5", "source_name": "Stock Titan", "published_at": "2025-08-07T20:06:58+00:00", "published_display": "07 Aug 2025 20:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 98, "total_relevant": 51, "sentiment_summary": {"positive": 7, "negative": 12, "neutral": 32, "score": 48, "total": 51, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "deals", "primary_label": "Deals and strategy", "confidence": 74, "events": [{"event": "deals", "label": "Deals and strategy", "weight": 10.8, "count": 19}, {"event": "general", "label": "Market update", "weight": 9.35, "count": 17}, {"event": "earnings", "label": "Earnings", "weight": 5.91, "count": 13}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 7, "negative_events": 12}, "market_context": {"has_market_context": true, "latest_close": 1.97, "latest_week": "2026-07-10", "one_week_move": 4.8, "four_week_move": -5.1, "twelve_week_move": -80.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.702993, "market_dynamics_buy_signal": false, "relative_strength": -80.753251, "fair_value_gap": -84.3, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 39.0244, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+4.8% over one week, -5.1% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 58, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Deals and strategy", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 11}, {"label": "TradingView", "count": 10}, {"label": "Market source", "count": 6}, {"label": "simplywall.st", "count": 3}, {"label": "StocksToTrade", "count": 2}, {"label": "PR Newswire", "count": 2}, {"label": "The Business Journals", "count": 1}, {"label": "TipRanks", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 42}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Deals and strategy", "count": 19}, {"label": "Market update", "count": 17}, {"label": "Earnings", "count": 13}, {"label": "Guidance", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "48/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Deals and strategy", "tone": "neutral", "text": "74/100 classification confidence."}, {"label": "Company focus", "value": "42", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+4.8% over one week, -5.1% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "NextCure (NASDAQ: NXTC) details Avere merger structure and S-4 plan"}], "updated_at": "2026-07-17T13:08:34.548695+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}